Patents by Inventor Irmingard Sures

Irmingard Sures has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel megakaryocytic protein tyrosine kinase 1
    Publication number: 20060263877
    Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and their use as diagnostic and therapeutic agents.
    Type: Application
    Filed: May 2, 2006
    Publication date: November 23, 2006
    Inventors: Axel Ullrich, Mikhail Gishizky, Irmingard Sures
  • Megakaryocytic protein tyrosine kinase I
    Patent number: 7037677
    Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryoctyes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2, and MKK3, and their use as diagnostic and therapeutic agents.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: May 2, 2006
    Assignees: Sugen, Inc., Max-Planck-Gessellschaft zur Forderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Mikhail Gishizky, Irmingard Sures
  • Megakaryocytic protein tyrosine kinase I
    Patent number: 6908984
    Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2, and MKK3, and their use as diagnostic and therapeutic agents.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: June 21, 2005
    Assignees: Sugen, Inc., Max-Planck-Gesellschaft zur Fonderung der Wissenschaften E.V.
    Inventors: Axel Ullrich, Mikhail Gishizky, Irmingard Sures
  • Novel megakaryocytic protein tyrosine kinases
    Publication number: 20030054527
    Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease.
    Type: Application
    Filed: October 16, 2001
    Publication date: March 20, 2003
    Applicant: SUGEN, INC.
    Inventors: Axel Ullrich, Mikhail Gishizky, Irmingard Sures
  • Novel megakaryocytic protein tyrosine kinases
    Publication number: 20020192790
    Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease.
    Type: Application
    Filed: October 16, 2001
    Publication date: December 19, 2002
    Applicant: SUGEN, INC. and MAX-PLANCK-GESSELLSCHAFT ZUR FONDERUNG DE WISSENSCHAFTEN E.V.
    Inventors: Axel Ullrich, Mikhail Gishizky, Irmingard Sures
  • Megakaryocytic protein tyrosine kinases
    Patent number: 6326469
    Abstract: The present invention relates to novel cytoplasmic tyrosine kinases isolated from megakaryocytes (megakaryocyte kinases or MKKs) which are involved in cellular signal transduction pathways and to the use of these novel proteins in the diagnosis and treatment of disease. The present invention further relates to specific megakaryocyte kinases, designated MKK1, MKK2 and MKK3, and their use as diagnostic and therapeutic agents.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: December 4, 2001
    Assignees: Sugen, Inc., Max-Planck-Gessellschaft zur Forderung der Wissenschaften e.V.
    Inventors: Axel Ullrich, Mikhail Gishizky, Irmingard Sures